Pathophysiological Analysis of Esophageal Motility Disorders Using Autoantibody Biomarkers and Exploration of Novel Biomarkers

Pathophysiological Analysis of Esophageal Motility Disorders Using Autoantibody Biomarkers and Exploration of Novel Biomarkers - E-MOTION (Esophageal MOtility disorders TIssue biomarkers ONe study)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058781

Enrollment

250

Registered

2025-08-13

Start date

2025-08-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with esophageal motility disorders such as achalasia and diffuse esophageal spasm

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients scheduled for blood tests, including those with and without esophageal motility disorders

Exclusion criteria

Exclusion criteria: Women who are pregnant or may be pregnant

Design outcomes

Primary

Measure	Time frame
The primary endpoint is to perform the MUSCAT Assay using plasma from patients with and without esophageal motility disorders and to compare the autoantibody results between the two groups.	—

Countries

Japan

Contacts

Public ContactMasaya Iwamuro

Okayama University Hospital Department of Gastroenterology

iwamuromasaya@yahoo.co.jp086-235-7219

Outcome results